COVID-19 vaccination in the United Kingdom

ISHLT and JHLT Share COVID-19 Vaccination Findings and Recommendations

Retrieved on: 
Thursday, May 13, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Bat virome, Severe acute respiratory syndrome, Vaccination, Medical specialties, COVID-19 vaccination in the United Kingdom

b'ADDISON, Texas, May 13, 2021 /PRNewswire/ -- Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients.

Key Points: 
  • b'ADDISON, Texas, May 13, 2021 /PRNewswire/ -- Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients.
  • Vaccination was safe with no evidence of short-term allograft-related adverse effects in either cohort.
  • "We also encourage the continued SARS-CoV-2 vaccination of SOT recipients and priority for vaccination of their household members and caregivers to reduce exposure risk for these vulnerable patients.
  • Importantly, the Journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.

Solution Needed to Address Increase in Vaccine Hesitancy for Medical, Religious, Philosophical Reasons Fueled by Johnson & Johnson COVID Vaccine Pause

Retrieved on: 
Friday, April 16, 2021
Medical research, COVID-19 vaccine, Vaccine hesitancy, Medicine, Health sciences, Health, COVID-19 vaccination in the United Kingdom, COVID-19 vaccination in Sweden

b'WILMINGTON, N.C., April 16, 2021 /PRNewswire/ --While various federal agencies recommend a pause in administering Johnson & Johnson\'s single-dose COVID-19 vaccine news outlets are reporting on the likelihood of it fueling an increase in vaccine hesitancy for medical, religious or philosophical reasons .

Key Points: 
  • b'WILMINGTON, N.C., April 16, 2021 /PRNewswire/ --While various federal agencies recommend a pause in administering Johnson & Johnson\'s single-dose COVID-19 vaccine news outlets are reporting on the likelihood of it fueling an increase in vaccine hesitancy for medical, religious or philosophical reasons .
  • For colleges and universities who mandate vaccines but are required by state law to accommodate waivers what\'s the path forward?\nOne solution currently on the market, CastleBranch\'s RealVaccinationID.com COVID-19 Waiver Card, provides a path forward for students who wish to be considered for a legally permissible waiver.
  • "\nPrior to being issued a card, individuals are asked to submit proof of their vaccination waiver status, along with their name, date of birth, address, photo ID and other personal identifiers.
  • A QR code and unique access code on the back of the card allows the cardholder to share their primary-source waiver documents with third parties but only with the cardholder\'s express permission and consent.\nRealVaccinationID.com COVID-19 Waiver Card builds upon the company\'s previous January 2021 release of the RealVaccinationID.com COVID-19 Vaccination Card, which helps individuals prove their COVID-19 vaccination status.\nRealVaccinationID.com is not a government-issued card, nor is it linked in any way to big tech.

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine

Retrieved on: 
Thursday, April 8, 2021
Health, Infectious diseases, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, COVID-19, Medicine, Medical research, Health sciences, COVID-19 vaccines, Clinical trials, RNA vaccines, Moderna COVID-19 vaccine, COVID-19 vaccine, Vaccine, Moderna, COVID-19 vaccination in the United Kingdom

We are pleased that this new data shows antibody persistence through 6 months following the second dose of our COVID-19 vaccine, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We are pleased that this new data shows antibody persistence through 6 months following the second dose of our COVID-19 vaccine, said Stphane Bancel, Chief Executive Officer of Moderna.
  • As detected by three distinct serologic assays, antibodies elicited by the Moderna COVID-19 vaccine persisted through 6 months after the second dose.
  • Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.
  • Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.

Rhode Island Stop & Shop Stores to Begin Administering COVID-19 Vaccines to Customers This Week

Retrieved on: 
Thursday, March 18, 2021
Medical specialties, Vaccination, Vaccine, Virology, Life sciences, Medicine, Stop & Shop, COVID-19 vaccination in the United Kingdom, COVID-19 vaccination in Bulgaria

Starting this week, select Stop & Shop locations will begin accepting online vaccination appointments for these populations.

Key Points: 
  • Starting this week, select Stop & Shop locations will begin accepting online vaccination appointments for these populations.
  • Stop & Shop expects all 14 of its pharmacy locations in Rhode Island to be administering either the two-dose vaccine series from Moderna or the single-dose Johnson & Johnson vaccine by next week.
  • Current eligible individuals must live, work or attend school in Rhode Island, and eligible customers can schedule their vaccination via Stop & Shops Online Vaccine Scheduling System.
  • The following Rhode Island Stop & Shop locations are expected to offer the Johnson & Johnson single-dose vaccine only.